Tax Inversion

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Five things for pharma marketers to know: Monday, December 1

Five things for pharma marketers to know: Monday, December 1

By By

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

By

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

AbbVie reconsiders Shire

AbbVie reconsiders Shire

By

AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.

Cosmo moves to Ireland

Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.

New Ireland tax rule does not fluster pharma

Ireland plans on closing off a tax advantage but pharma does not appear to flinch.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

By

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Five things for Pharma Marketers to know: Monday, September 29

Five things for Pharma Marketers to know: Monday, September 29

By

Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Walgreen keeps US tax status

The Illinois company says it is keeping the US as its home base, which means no inversion benefit.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

By

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Shire asks AbbVie for more money

Shire asks AbbVie for more money

By

Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Salix heads to Ireland

Salix heads to Ireland

By

Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.